Also trades as: 0L35.L (LSE) · $vol 0M
SRPT NASDAQ
Sarepta Therapeutics, Inc.
1W: -6.3%
1M: -24.6%
3M: -8.8%
YTD: -17.9%
1Y: -9.4%
3Y: -85.8%
5Y: -80.7%
$17.50
-0.07 (-0.40%)
Weekly Expected Move ±8.4%
$15
$16
$18
$19
$20
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-09-19
Earliest Filing
2024-11-26
Latest Filing
partner: 1
investor: 1
Counterparties (Filed by SRPT)
2 relationshipsCompanies named in SRPT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | ARQT | partner | Sarepta entered into an exclusive license and collaboration agreement for siRNA therapies and a stock purchase agreement | 2024-11-26 | View |
| Michael A. Chambers Living Trust | — | investor | Affiliated investor purchasing notes in a private placement. | 2022-09-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-23 | Material Agreement | Agreement | View |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-25 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-19 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-12-11 | Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-08 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-29 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Other Events; Fin | Agreement | View |
| 2025-08-21 | Unregistered Sales of Equity Securities | View | |
| 2025-08-13 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-07-21 | Other Events | View | |
| 2025-07-16 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; De | View | |
| 2025-06-06 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-14 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR